Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • ML133 HCl: Molecular Insights into Kir2.1 Inhibition and ...

    2026-04-07

    ML133 HCl: Molecular Insights into Kir2.1 Inhibition and Pulmonary Vascular Remodeling

    Introduction

    Inward rectifier potassium (Kir) channels are pivotal for maintaining membrane potential, cellular excitability, and homeostasis in excitable and non-excitable cells alike. Among these, the Kir2.1 potassium channel stands out for its role in cardiovascular physiology, especially in pulmonary artery smooth muscle cells (PASMCs), vascular remodeling, and disease pathogenesis. The advent of highly selective Kir2.1 channel blockers like ML133 HCl (SKU B2199) has revolutionized the study of potassium channel modulation and its downstream effects in health and disease.

    While previous articles have highlighted the practical benefits of ML133 HCl in workflow optimization and assay reproducibility, this comprehensive review delves deeper into the molecular mechanisms, experimental nuances, and emerging applications of ML133 HCl in cardiovascular and pulmonary vascular research. By integrating recent breakthroughs in Kir2.1 channel pharmacology and referencing the seminal findings of Cao et al. (2022) (DOI: 10.3892/ijmm.2022.5175), we aim to provide a uniquely mechanistic and translational perspective for advanced ion channel studies.

    The Molecular Basis of Kir2.1 Potassium Channel Function

    Kir2.1 in Vascular Physiology and Pathophysiology

    Kir2.1, encoded by the KCNJ2 gene, is a classical inward rectifier potassium channel subtype expressed in cardiac and vascular smooth muscle cells. Its primary function is to stabilize resting membrane potential and regulate potassium ion transport, thereby influencing smooth muscle cell excitability, contraction, and proliferation. Dysregulation of Kir2.1 has been implicated in arrhythmias, pulmonary hypertension, and vascular remodeling, making it a critical target for cardiovascular potassium channel studies and drug discovery.

    Kir2.1 and Pulmonary Artery Smooth Muscle Cell Proliferation

    Abnormal proliferation and migration of PASMCs are hallmark features of pulmonary vascular disease and remodeling, particularly in pulmonary hypertension. Kir2.1 modulates PASMC proliferation and migration through its control of membrane potential and interaction with key signaling pathways such as TGF-β1/SMAD2/3. The recent study by Cao et al. (2022) (DOI: 10.3892/ijmm.2022.5175) demonstrated that Kir2.1 expression is upregulated in pulmonary hypertension models, and its inhibition can reverse pathological proliferation and migration, highlighting its central role in pulmonary vascular remodeling.

    ML133 HCl: A Selective and Potent Kir2.1 Channel Inhibitor

    Biochemical and Pharmacological Properties

    ML133 HCl, chemically known as 1-(4-methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine hydrochloride, is a highly selective potassium channel inhibitor designed to target Kir2.1 channels. With an IC50 of 1.8 μM at pH 7.4 and 290 nM at pH 8.5, ML133 HCl demonstrates potent inhibition of Kir2.1, while exhibiting negligible effects on Kir1.1 and only weak activity against Kir4.1 and Kir7.1. This selectivity ensures that experimental outcomes are attributable to Kir2.1 inhibition, minimizing confounding off-target effects.

    ML133 HCl is supplied as a solid, insoluble in water but readily dissolved in DMSO (≥15.7 mg/mL) or ethanol (≥2.52 mg/mL) with gentle warming and ultrasonic treatment. For optimal stability, it should be stored at -20°C and prepared fresh for each experiment. The compound is provided by APExBIO at ≥98% purity, supported by HPLC, NMR, and MSDS documentation, ensuring reproducibility and traceability for rigorous potassium channel research.

    Mechanism of Kir2.1 Inhibition by ML133 HCl

    ML133 HCl acts as a selective Kir2.1 channel blocker, binding to the channel and preventing potassium ion flow. This action disrupts the maintenance of resting membrane potential and modulates downstream signaling. Unlike non-selective potassium channel inhibitors, ML133 HCl enables precise dissection of Kir2.1-specific physiological and pathophysiological roles. Its selectivity is critical for exploring the nuances of Kir2.1 channel pharmacology, particularly in complex tissues or cardiovascular disease models where multiple Kir subtypes coexist.

    ML133 HCl in Pulmonary Artery Smooth Muscle Cell Proliferation and Migration Assays

    Experimental Insights from Recent Research

    The functional relevance of Kir2.1 inhibition was elegantly demonstrated in the study by Cao et al. (2022), which employed ML133 as a tool compound to interrogate PASMC biology. In vitro, pretreatment of human PASMCs with ML133 HCl for 24 hours, followed by stimulation with PDGF-BB, resulted in a marked reduction in both proliferation and migration, as assessed by scratch and Transwell assays. ML133 also suppressed the upregulation of osteopontin (OPN) and proliferating cell nuclear antigen (PCNA), markers of cellular activation, and inhibited the TGF-β1/SMAD2/3 signaling pathway.

    In vivo, a monocrotaline-induced pulmonary hypertension model revealed increased Kir2.1 expression and activation of pathogenic pathways in pulmonary vasculature. Pharmacological inhibition with ML133 reversed these molecular and cellular changes, demonstrating its utility as a research tool for dissecting the mechanisms of pulmonary vascular remodeling and for modeling cardiovascular disease processes in animal and cellular systems.

    Distinguishing Features for Advanced Potassium Channel Research

    Unlike broad overviews or workflow-centric guides such as this article on advanced research applications, which focus on technical deployment of ML133 HCl in standard methodologies, our analysis emphasizes the underlying molecular mechanisms and translational implications of selective Kir2.1 channel blockade. This deeper perspective facilitates hypothesis-driven research and the development of novel therapeutic strategies targeting ion channel signaling in vascular disease.

    Comparative Analysis: ML133 HCl Versus Alternative Kir2.1 Inhibition Strategies

    Genetic Versus Pharmacological Approaches

    Traditional approaches to Kir2.1 inhibition include gene knockdown (e.g., siRNA, shRNA) or knockout models, which provide high specificity but may suffer from compensatory upregulation of other channels or long-term cellular adaptation. In contrast, ML133 HCl enables acute and reversible inhibition of Kir2.1, allowing for temporal control and minimizing compensatory confounders. This is particularly advantageous for studies requiring rapid modulation of potassium channel activity, such as real-time electrophysiological recordings or short-term signaling assays.

    Specificity and Experimental Control

    The specificity of ML133 HCl for Kir2.1, with minimal activity against related Kir channels, distinguishes it from non-selective potassium channel blockers (e.g., Ba2+, Cs+), which can interfere with multiple ion channel families. This selectivity underpins its value in dissecting the unique contributions of Kir2.1 to cardiovascular and pulmonary physiology, as well as in modeling disease mechanisms and evaluating the efficacy of novel ion channel inhibitors.

    For practical workflow optimization and troubleshooting in cell-based assays, readers may wish to consult guides such as this scenario-driven reference. While those articles focus on assay design and reproducibility, the present review prioritizes mechanistic depth and translational relevance.

    Advanced Applications of ML133 HCl in Ion Channel Pharmacology

    Modeling Pulmonary Hypertension and Vascular Disease

    ML133 HCl is increasingly utilized in sophisticated models of pulmonary hypertension, allowing researchers to probe the contributions of potassium channel Kir2.1 to vascular remodeling, PA smooth muscle cell proliferation, and disease progression. By facilitating precise inhibition of Kir2.1, ML133 HCl enables the dissection of complex signaling networks (e.g., TGF-β1/SMAD2/3) and the identification of druggable nodes in cardiovascular pathology. These insights are driving new approaches to cardiovascular potassium channel studies and potassium channel drug discovery.

    Electrophysiology and Ion Channel Signaling

    ML133 HCl is well-suited for patch-clamp and high-throughput electrophysiology experiments, where its rapid, selective action on Kir2.1 channels permits direct observation of channel kinetics, voltage dependence, and pharmacological modulation. Such studies are essential for validating new ion channel inhibitors, quantifying the effects of disease mutations, and elucidating the role of Kir2.1 in ion channel signaling cascades.

    Expanding into Translational and Personalized Medicine

    As research advances, ML133 HCl is being incorporated into translational studies aiming to bridge basic ion channel pharmacology with clinical applications. For example, selective Kir2.1 inhibition is being explored in patient-derived cells and complex tissue models to assess potential efficacy and safety in pulmonary hypertension, arrhythmias, and vascular disorders. This translational focus distinguishes our review from prior articles emphasizing protocol optimization, offering a forward-looking perspective on the future of potassium channel research and therapeutics.

    Technical Considerations and Best Practices

    Preparation, Solubility, and Storage

    For experimental consistency, ML133 HCl should be dissolved in DMSO or ethanol with gentle warming and ultrasonic agitation to achieve full solubility. Solutions should be freshly prepared before each experiment, as long-term storage may compromise compound integrity. All experimental protocols should include proper controls and documentation, leveraging the high purity and quality control data provided by APExBIO to ensure reproducible outcomes.

    Recommended Concentrations and Controls

    Based on published studies and product documentation, effective concentrations of ML133 HCl in cell-based assays range from 0.5 to 10 μM, depending on the system and endpoint. Appropriate vehicle controls (DMSO or ethanol) and, when possible, genetic knockout or overexpression models should be integrated to validate specificity and interpret results within the broader context of potassium channel modulation.

    Conclusion and Future Outlook

    ML133 HCl has emerged as a transformative tool in potassium channel research, enabling selective inhibition of Kir2.1 and uncovering new mechanisms in pulmonary artery smooth muscle cell proliferation, migration, and vascular remodeling. By facilitating precise dissection of ion channel signaling pathways—such as the TGF-β1/SMAD2/3 axis—ML133 HCl is catalyzing advances in cardiovascular disease modeling, drug discovery, and translational medicine.

    As the field evolves, the integration of ML133 HCl into high-throughput screening, patient-derived models, and systems biology approaches promises to accelerate the understanding of Kir channel physiology and the development of targeted therapies for pulmonary hypertension, arrhythmias, and related vascular diseases. For detailed product specifications and ordering information, visit the ML133 HCl product page (SKU B2199) on the APExBIO website.

    For additional scenario-driven workflow strategies or technical Q&A, readers may reference prior literature such as this practical guide, which complements the mechanistic and translational perspective provided herein.